Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 2/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6390513 | 0.89 | MAPT (0.56) | PARGMMP13SLC22A8HPGDTP53 | |
| SCHEMBL6396627 | 0.88 | PARG (0.47) | PARGMMP13SLC22A8HDAC1MAPT | |
| SCHEMBL6389394 | 0.87 | PARG (0.47) | PARGMMP13SLC22A8TP53HDAC1 | |
| SCHEMBL6391387 | 0.87 | MMP13 (0.46) | PARGMMP13SLC22A8HPGDHDAC1 | |
| SCHEMBL6390068 | 0.86 | MAPT (0.50) | PARGMMP13SLC22A8HPGDTP53 | |
| SCHEMBL6247398 | 0.86 | MMP13 (0.64) | PARGMMP13SLC22A8HDAC1MAPT | |
| SCHEMBL10084721 | 0.85 | TP53 (0.63) | PARGMMP13SLC22A8BRD4TP53 | |
| SCHEMBL19555085 | 0.83 | MAPK8 (0.66) | PARGADORA3ADORA2BTP53HDAC1 | |
| SCHEMBL6390779 | 0.82 | MMP13 (0.42) | PARGMMP13SLC22A8HDAC1 | |
| SCHEMBL6241073 | 0.82 | MMP13 (0.71) | PARGMMP13SLC22A8HPGDHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | PARG 3624/4885MMP13 1/4885SLC22A8 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.